Welcome
Research Opportunities
Impact
Programs
Partners
Management
Faculty
Symposium
Workshops
Links
for OCITS Scientists
Contact Us



Impact of ORDCF
Strengths |  Impact of ORDCF |  Available Positions at OCITS


Image-guided minimally-invasive therapy and surgery is emerging as a major new healthcare sector due to its profound impact on the quality and cost-effectiveness of patient care. Tumours can be eradicated more effectively and hospital stays reduced due to the minimally invasive procedures. In radiation therapy of cancer, the costs of retreatment following failure are typically three times higher than the initial course of therapy. New technologies are being developed for urology, oncology, neurosurgery and orthopedics. All have potentially major commercial markets.


The rationale for a consortium in this field is the common nature of the technological problems encountered in the patient applications. For example, software algorithms developed to guide the insertion of energy sources or needles under image guidance will be similar whether the application is ultrasound guided microwave thermal therapy for prostate cancer or MRI guided needle biopsy of brain tumours. The interdisciplinary nature of this field is illustrated below where the side "bookends" represent the convergent specialties of imaging and therapy which we aim to bring closer together though this consortium. The circles show the technology platforms common to image guided therapy and surgery which represent the opportunities for linkage between the consortium research projects. The inner boxes represent the commercial opportunities for medical application of these technology platforms.

The added value of OCITS in this field of common technological challenges is the cross-fertilization of ideas within the consortium. This will spur the development of unique intellectual property that merges imaging and therapy technologies to alleviate the disabling effects, lost productivity, and costs of disease or treatment complications. Companies involved in the consortium will be in a position to commercialize the intellectual property not only through individual project but also through the partnerships that will result from consortium activity. These new partnerships will allow the development of a globally competitive industry in Ontario in this field. An example of the type of partnership OCITS will facilitate is between CADMIT and CPCI, two of our Ontario small companies. They are developing different aspects of ultrasound guided thermal therapy for prostate cancer, treatment planning (CADMIT), 3D ultrasound guidance and treatment delivery (CPCI). The work by the OCITS consortium will provide the linking science that allows these technologies to be bundled in more effective and competitive products for the prostate cancer market.


Top
Terms and Conditions | Privacy Policy
Copyright © 2001-2006 University Health Network. All rights reserved.
Last modified Friday, June 13, 2008